Mannkind (MNKD) Other Operating Expenses (2014 - 2026)
Mannkind (MNKD) reported Other Operating Expenses of $20.5 million for Q1 2026, up 2.48% year-over-year from $20.0 million in Q1 2025, and down 39.0% on a QoQ basis from $33.6 million in Q4 2025.
Mannkind (MNKD) has 13 years of Other Operating Expenses data on file, last reported at $20.5 million in Q1 2026.
- Quarterly Other Operating Expenses rose 2.48% year-over-year to $20.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $100.2 million (up 32.65% YoY) and the FY2025 annual result came in at -$27.1 million, up 52.89% from the prior year.
- Other Operating Expenses declined to $20.5 million in Q1 2026 per MNKD's latest filing, from $33.6 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $33.6 million in Q4 2025 and bottomed at -$28.8 million in Q2 2022.
- The 5-year median for Other Operating Expenses is $17.2 million (2024), against an average of $5.7 million.
- The widest annual swing landed in 2022, when Other Operating Expenses plunged 782.42%; it then soared 476.98% in 2024.
- Tracing MNKD's Other Operating Expenses over 5 years: stood at -$17.9 million in 2022, then slipped by 10.93% to -$19.9 million in 2023, then jumped by 176.2% to $15.2 million in 2024, then soared by 121.76% to $33.6 million in 2025, then tumbled by 39.0% to $20.5 million in 2026.
- Per Business Quant, the three latest MNKD Other Operating Expenses figures stand at $20.5 million (Q1 2026), $33.6 million (Q4 2025), and $20.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.52 Mn |
| Dec 31, 2025 | 33.64 Mn |
| Sep 30, 2025 | 20.08 Mn |
| Jun 30, 2025 | 25.93 Mn |
| Mar 31, 2025 | 20.03 Mn |
| Dec 31, 2024 | 15.17 Mn |
| Sep 30, 2024 | 20.48 Mn |
| Jun 30, 2024 | 19.85 Mn |
| Mar 31, 2024 | 17.20 Mn |
| Dec 31, 2023 | -19.91 Mn |
| Sep 30, 2023 | 25.63 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.12 Mn |
| Jun 30, 2022 | -28.76 Mn |
| Mar 31, 2022 | -25.74 Mn |
| Dec 31, 2021 | -27.80 Mn |
| Sep 30, 2021 | -4.26 Mn |
| Jun 30, 2021 | -35.55 Mn |
| Mar 31, 2021 | 3.77 Mn |
| Dec 31, 2020 | 57.89 Mn |
| Sep 30, 2020 | 9.10 Mn |
| Jun 30, 2020 | 7.90 Mn |
| Mar 31, 2020 | 7.25 Mn |
| Dec 31, 2019 | 9.60 Mn |
| Sep 30, 2019 | 5.13 Mn |
| Jun 30, 2019 | 7.71 Mn |
| Mar 31, 2019 | 3.62 Mn |
| Dec 31, 2018 | 4.70 Mn |
| Sep 30, 2018 | 4.58 Mn |
| Jun 30, 2018 | -268,000.00 |
| Mar 31, 2018 | 6.99 Mn |
| Dec 31, 2017 | 6.58 Mn |
| Sep 30, 2017 | 8.14 Mn |
| Jun 30, 2017 | 12.05 Mn |
| Mar 31, 2017 | 4.09 Mn |
| Dec 31, 2016 | 7.34 Mn |
| Sep 30, 2016 | 27.07 Mn |
| Jun 30, 2016 | 3.70 Mn |
| Mar 31, 2016 | 7.53 Mn |
| Dec 31, 2015 | 258.33 Mn |
| Sep 30, 2015 | 8.62 Mn |
| Jun 30, 2015 | 5.69 Mn |
| Mar 31, 2015 | 1.88 Mn |
| Dec 31, 2014 | 3.56 Mn |